Objective:To analyze the registration status of clinical trials related to contraceptives based on the data of World Health Organization International Clinical Trials Registry Platform (ICTRP), so as to understand the situation of contraceptives development, and provide reference for improving the quality of clinical trials.Methods:All records in the database of ICTRP before January 1, 2025 was researched to screen out contraceptives clinical trials, and the registration time, registration platform, regional distribution, trial design and research content were analyzed.Results:A total of 206 clinical trials related to contraceptives were included. The projects were mainly carried out in the United States, Germany, and India. About 95.63% (197/206) of the study subjects were women of reproductive age. The　main　type　of　study　was　intervention [89.32% (184/206)], among which random trials accounted for 53.26% (98/184), and parallel group trials were the most common [82.65% (81/98)]. Over 64.56% (133/206) of the trials were indicated with open-label. Most of the clinical trials were in phase Ⅲ [47.57% (98/206)] and phase Ⅳ [16.50% (34/206)]. The interventions in female studies were mainly in three aspects: oral contraceptive [42.64% (84/197)], intrauterine delivery [15.23% (30/197)], and vaginal delivery [15.23% (30/197)], and the primary outcome included pregnancy rate [54.82% (108/197)], adverse drug reactions [13.20% (26/197)], ovulation inhibition [8.63% (17/197)], and vaginal infection [4.06% (8/197)].Conclusion:The　clinical　trials　of contraceptives were unevenly distributed, the research types were mainly randomized interventional trials, the included participants were mainly women of reproductive age, the intervention measures were mostly oral contraceptive, intrauterine delivery and vaginal delivery.

Objective:To analyze the registration status of clinical trials related to contraceptives based on the data of World Health Organization International Clinical Trials Registry Platform (ICTRP), so as to understand the situation of contraceptives development, and provide reference for improving the quality of clinical trials.Methods:All records in the database of ICTRP before January 1, 2025 was researched to screen out contraceptives clinical trials, and the registration time, registration platform, regional distribution, trial design and research content were analyzed.Results:A total of 206 clinical trials related to contraceptives were included. The projects were mainly carried out in the United States, Germany, and India. About 95.63% (197/206) of the study subjects were women of reproductive age. The　main　type　of　study　was　intervention [89.32% (184/206)], among which random trials accounted for 53.26% (98/184), and parallel group trials were the most common [82.65% (81/98)]. Over 64.56% (133/206) of the trials were indicated with open-label. Most of the clinical trials were in phase Ⅲ [47.57% (98/206)] and phase Ⅳ [16.50% (34/206)]. The interventions in female studies were mainly in three aspects: oral contraceptive [42.64% (84/197)], intrauterine delivery [15.23% (30/197)], and vaginal delivery [15.23% (30/197)], and the primary outcome included pregnancy rate [54.82% (108/197)], adverse drug reactions [13.20% (26/197)], ovulation inhibition [8.63% (17/197)], and vaginal infection [4.06% (8/197)].Conclusion:The　clinical　trials　of contraceptives were unevenly distributed, the research types were mainly randomized interventional trials, the included participants were mainly women of reproductive age, the intervention measures were mostly oral contraceptive, intrauterine delivery and vaginal delivery.

Currently, the major task of reproductive pharmacology is fertility preservation. Aside from studying the efficacy of contraceptives, the research area of reproductive pharmacology has been expanded to probe into the pharmacodynamics and the mechanism of action of medications for treatment of reproductive system disease and assisted fertility as well. The development of analysis techniques, including genomics, transcriptomics, metabolomics, proteomics, organoid culture, stem cell technology and single cell sequencing, provide multiple ways to explore therapeutic targets and new mechanisms of the treatment approaches. With the changes of age structure diagram in China population accompanied with coexisting lower fertility, higher abortion rate and increased number of seniors, more attention in the area of reproductive pharmacology should be paid on the research and development of contraceptives suitable for the young and the unmarried girls to avoid unnecessary abortion and preserve their fertility and provide more opportunities for those who willing to have children, extending their the reproductive span. Furthermore, pharmacological effects, especially the impact and outcomes of assisted reproductive technology and pertaining products on the health of the offspring should be paid more investigation and concerned, which belong to a part of the basic national policy of eugenics and are crucial to enhance the population quality of all the nationalities. This is a major challenge for the reproductive pharmacology researchers faced.

Currently, the major task of reproductive pharmacology is fertility preservation. Aside from studying the efficacy of contraceptives, the research area of reproductive pharmacology has been expanded to probe into the pharmacodynamics and the mechanism of action of medications for treatment of reproductive system disease and assisted fertility as well. The development of analysis techniques, including genomics, transcriptomics, metabolomics, proteomics, organoid culture, stem cell technology and single cell sequencing, provide multiple ways to explore therapeutic targets and new mechanisms of the treatment approaches. With the changes of age structure diagram in China population accompanied with coexisting lower fertility, higher abortion rate and increased number of seniors, more attention in the area of reproductive pharmacology should be paid on the research and development of contraceptives suitable for the young and the unmarried girls to avoid unnecessary abortion and preserve their fertility and provide more opportunities for those who willing to have children, extending their the reproductive span. Furthermore, pharmacological effects, especially the impact and outcomes of assisted reproductive technology and pertaining products on the health of the offspring should be paid more investigation and concerned, which belong to a part of the basic national policy of eugenics and are crucial to enhance the population quality of all the nationalities. This is a major challenge for the reproductive pharmacology researchers faced.

Object To study the inherited relationships among nine medicinal mulberry populations cultivated in different regions of Xinjiang at DNA level Methods DNA of all populations was amplified by ten random primers from 100 ramdom primers, the polymorphic bands of RAPD were counted And the results of populations were analyzed by clustering analysis NTSYS PC software Results A total of 108 bands was obtained, 91 of total bands (84 26%) was polymorphic The results indicated that there were apparent and abundant genetic variations in Morus L of Xinjiang Besides, eight specific bands of M nigra were obtained Conclusion The genetic relationship among medicinal resources plants of mulberry in Xinjiang indicats by the RAPD analysis to be consistent with their traditional classifications in the main

AIM: To optimize the extraction process of the total flavonoids of Pollen typhae. METHODS: The optimum extraction process was selected with the orthogonal design (L 27 (3 13 )), using the contents of typhaneoside and isorhamnetin 3 O neohesperidoside as the evaluating criteria. RESULTS: The significant effects of alcohol concentration, extraction time and extraction times on the extraction of the total flavonoids of Pollen typhae were discovered. CONCLUSION: The optimum extraction process was as follows: Pollen typhae was extracted with 40% alcohol for two times, each with the solvent volume 14 times of the weight of the raw materials and extraction time for 3 h.